Advertisement

Topics

Clinical Trials About "AbbVie Unjustified Humira Settlements Divide Market Claims Class" RSS

19:15 EDT 19th June 2019 | BioPortfolio

We list hundreds of Clinical Trials about "AbbVie Unjustified Humira Settlements Divide Market Claims Class" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "AbbVie Unjustified Humira Settlements Divide Market Claims Class" on BioPortfolio

We have published hundreds of AbbVie Unjustified Humira Settlements Divide Market Claims Class news stories on BioPortfolio along with dozens of AbbVie Unjustified Humira Settlements Divide Market Claims Class Clinical Trials and PubMed Articles about AbbVie Unjustified Humira Settlements Divide Market Claims Class for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AbbVie Unjustified Humira Settlements Divide Market Claims Class Companies in our database. You can also find out about relevant AbbVie Unjustified Humira Settlements Divide Market Claims Class Drugs and Medications on this site too.

Showing "AbbVie Unjustified Humira Settlements Divide Market Claims Class" Clinical Trials 1–25 of 2,000+

Extremely Relevant

Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination"

This study is a non-interventional, observational study of Humira® in the treatment of pediatric CD as per the New Drug Re-examination Guideline in Korea. This study will be conducted in institutions which provide a written agreement to AbbVie Korea, and where the use of Humira® for pediatric CD is following their normal medical practice setting. Pediatric patients who are prescribed Humira® as per physician's medical judgment in accordance with the approved Summary of Produ...


Relevant

To Compare the Pharmacokinetics and Safety of CT-P17 and Humira (US Licensed Humira and EU-approved Humira) in Healthy Subjects

A Phase 1, Randomized, Double-blind, Three-arm, Parallel group, Single-dose Study to Compare the Pharmacokinetics and Safety of CT-P17 and Humira (US licensed Humira and EU-approved Humira) in Healthy Subjects

Adalimumab PK Bioequivalence Study to EU and US Sourced Humira

Double-Blind, 3-Way Parallel Study to Compare the Pharmacokinetics, Safety and Tolerability of BMO-2 to EU and US Sourced Humira® Administered as a Single Dose (40 mg) Subcutaneous Injection in Healthy Adults.


This Trial Compares BI 695501 and Humira® in Patients With a Long-term Disease That Causes Red, Scaly Patches on the Skin (Plaque Psoriasis). The Trial Looks at the Way the Body Takes up the Drugs and How Effective and Safe They Are

The primary objective of the trial is to assess the PK similarity between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®, in patients with moderate-to-severe chronic plaque psoriasis. The secondary objectives of this trial are to descriptively compare the safety, immunogenicity and efficacy profiles between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®.

Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

Velcade (bortezomib, PS-341) has recently been approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM) for patients who have received at least one prior therapy. Velcade is a unique compound developed by scientists at Millennium Pharmaceuticals, Inc. Velcade enters cells and affects the way they divide. Cancer cells are particularly sensitive. Velcade interferes with the enzyme "proteasome" which is responsible for allowing cells to divide...

Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)

This study has been designed as a multicentre, randomised, double-blind study of AVT02 in healthy adult subjects. The study will assess the PK, safety and tolerability of AVT02 compared to EU-Humira and US licenced Humira (US-Humira), when administered as a single 40 mg SC dose.

EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries

This is a non-interventional, post-marketing, observational study (PMOS) in which HUMIRA® (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose, population and indication. No data currently exists to characterize patient populations being prescribed HUMIRA® in Eastern Europe. Further, it is important to establish the clinical outcome and tolerability of HUMIRA® in Eastern European patients, as...

Surveillance of Humira Injection in Korean Patients

Patients who take Humira as prescribed by physicians as per Korean label will be enrolled and observed in normal medical practice setting for not less than 3 months following first dose of Humira. Information on demographics, diagnosis and medical history, results of tuberculosis skin test, results of chest X-ray, Humira treatment information, concomitant medication, physician's global assessment for effectiveness, disease activity assessment for rheumatoid arthritis, disease ...

Study to Demonstrate Non-Inferiority Efficacy and Safety of CinnoRA® Produced by CinnaGen Company Versus Humira® for Treatment of Active Rheumatoid Arthritis

The purpose of this study is to compare the efficacy and safety of adalimumab produced by CinnaGen company and AbbVie adalimumab in subjects with active Rheumatoid Arthritis. Patients with diagnosis of active Rheumatoid arthritis according to EULAR criteria (European League Against Rheumatism) aged between 18 to 75 years are included. This is a Phase III, randomized, two arms, double blind (patient and assessor blinded), parallel active non inferiority controlled clinical trial...

Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?

Studies on tumor necrosis factor alpha antagonist (anti-TNF) therapy in rheumatoid arthritis (RA) patients have found that erosive damage may "heal" in some RA patients treated with anti-TNF. Repeated examinations of adalimumab (Humira) treated RA patients, using computed tomography (CT), magnetic resonance imaging (MRI), ultrasonography (US) and radiography will allow detailed assessment of the extent of bone repair/healing during adalimumab (Humira) therapy.

Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers

Adalimumab is an immunosuppressive drug that belongs to the family of anti-TNF agents. It contains a monoclonal antibody produced by biotechnology. It is designed to bind to tumor necrosis factor (TNF), a substance that is involved in several auto-immune processes. By binding to TNF, adalimumab blocks its activity, reducing the severity of various chronic inflammatory diseases including Rheumatoid Arthritis, Plaque Psoriasis and others. Often, the high cost of biologic product...

Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

The purpose of this study is to determine the safety and efficacy of Humira in the treatment of pyoderma gangrenosum.

MYL-1401A Efficacy and Safety Comparability Study to Humira®

To assess the equivalence of MYL-1401A to Humira® with regards to efficacy in subjects with moderate-to-severe chronic plaque psoriasis

Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness

This study assesses Humira's® real-life effectiveness in the management of dermatological manifestations of moderate to severe Hidradenitis Suppurativa (HS).

Efficacy and Safety of Humira in Patients With Psoriatic Arthritis in Normal Medical Practice

This study is a documentation of effectiveness and safety of Humira in patients with psoriatic arthritis.

Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis

The purpose of this study is to determine the safety and efficacy of Humira in the treatment of cutaneous sarcoidosis.

A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects

This study aims to demonstrate pharmacokinetic (PK) similarity of biosimilar candidate CinnoRA® relative to adalimumab reference product (Humira®) and evaluate safety and tolerability of CinnoRA®, in a parallel fashion in healthy volunteers after administration of a single dose (40 mg) of adalimumab. The primary objective of this study is to demonstrate that the PK of CinnoRA® is similar to its originator, Humira®, as assessed by the area under the serum concentration tim...

Juvenile Idiopathic Arthritis (JIA) Registry

This is a global registry, to evaluate the long-term safety of Humira® in patients with moderate to severe polyarticular JIA, that are treated as recommended in the Humira® product label. Patients treated with MTX will be considered a reference group. Patients will be followed in both the Humira® and MTX arms will be followed for 10 years.

Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis

CALYPSO clinical study is a phase 3 study which is carried out to establish the efficacy, safety and pharmacokinetic equivalence of BCD-055 (adalimumab, manufactured by JSC BIOCAD, Russia) and Humira® when used in patients with moderate to severe plaque psoriasis.

HIV Treatment and CVD Events

Cardiovascular disease (CVD) has been associated with HIV infection. However, it is uncertain whether increased CVD rates are associated with HIV-related factors (e.g., HIV-infection or highly active antiretroviral therapy (HAART) may worsen dyslipidemia) or reflect differences in the prevalence of underlying risk factors for CVD. Furthermore, the association between initiation and duration of HAART exposure and CVD risk, including which specific drugs within the HAART classes ...

Special Investigation of Humira on Long-term Treatment in Patients With Rheumatoid Arthritis

The present survey will be conducted to collect information on the safety (especially the development of malignant tumors, infections, and other untoward events) and effectiveness of Humira 40 mg/0.8 mL Syringe for Subcutaneous Injection (Humira) in patients receiving the drug for a long period of time for the treatment of rheumatoid arthritis, for the purpose of investigating and confirming factors affecting the safety and effectiveness of the drug.

A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy

This is a randomized, double-blind, parallel group, multicenter clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of LBAL compared to Humira® in subjects with active Rheumatoid Arthritis despite Methotrexate therapy.

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice

Safety and Effectiveness of adalimumab (Humira) in Psoriasis Patients in Routine Clinical Practice.

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures

The purpose of this study is to evaluate the efficacy and safety of triple therapy of AbbVie adults with chronic hepatitis C virus ("HCV"), who have not responded to prior treatment with protease inhibitors. The "Triple therapy" of AbbVie attacks various sites of the viral genome, thus increasing the potential efficacy of the treatment, especially for patients who have failed PI treatment.

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis

Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis


More From BioPortfolio on "AbbVie Unjustified Humira Settlements Divide Market Claims Class"

Advertisement
Quick Search
Advertisement
Advertisement